Mise au point sur l’utilisation du fentanyl transmuqueux chez le patient présentant des douleurs d’origine cancéreuse (version longue)
- 30 June 2012
- journal article
- research article
- Published by JLE in Douleur et Analgésie
- Vol. 25 (2) , 102-117
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough painJournal of Opioid Management, 2010
- The Role of Fentanyl in Cancer-Related PainJournal of Palliative Medicine, 2009
- Bioequivalence Following Buccal and??Sublingual Placement of Fentanyl??Buccal Tablet 400????g in??Healthy SubjectsClinical Drug Investigation, 2008
- Absorption of Fentanyl from Fentanyl Buccal Tablet in Cancer Patients With or Without Oral MucositisClinical Drug Investigation, 2007
- Comparison of Equivalent Doses of Fentanyl Buccal Tablets and Arteriovenous Differences in Fentanyl PharmacokineticsClinical Pharmacokinetics, 2006
- Fentanyl Buccal TabletDrugs, 2006
- Evidence-Based Oral Transmucosal Fentanyl Citrate (OTFC®) Dosing GuidelinesPain Medicine, 2005
- Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident painBritish Journal of Clinical Pharmacology, 2005
- A Pharmacokinetic Study to Compare Two Simultaneous 400 μg Doses with a Single 800 μg Dose of Oral Transmucosal Fentanyl CitrateJournal of Pain and Symptom Management, 2003